PAC-14028

Summary

Pac-14028 (CHEMBL3707398) is a phase-3 clinical-stage unknown targeting TRPV1; indicated across 4 conditions including atopic eczema and rosacea.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Targets: 1 (TRPV1)
• Indications: 4 conditions
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3707398
Name	PAC-14028
Type	Unknown
Max phase	3

Also known as: Asivatrep, Pac-14028, PAC-14028

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
TRPV1	TRPV1	Antagonist	8.21	0.3%	Q8NER1

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): TRPV1.

Top Reactome pathways

1 total, by targets touching each:

Pathway	Targets	Genes
TRP channels	1	TRPV1

Dominant GO biological processes

GO term	Targets
negative regulation of transcription by RNA polymerase II	1
fever generation	1
diet induced thermogenesis	1
peptide secretion	1
lipid metabolic process	1
cell surface receptor signaling pathway	1
chemosensory behavior	1
cellular response to heat	1
behavioral response to pain	1
sensory perception of taste	1
sensory perception of mechanical stimulus	1
thermoception	1
detection of temperature stimulus involved in thermoception	1
detection of temperature stimulus involved in sensory perception of pain	1
detection of chemical stimulus involved in sensory perception of pain	1

Indications & clinical

Indications

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
atopic eczema	3	MONDO:0004980	EFO:0000274
rosacea	2	MONDO:0006604	EFO:1000760
seborrheic dermatitis	2	MONDO:0006608	EFO:1000764

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE1	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02052531	PHASE2	COMPLETED	Evaluation of the Antipruritic Effect of PAC-14028 Cream in Skin Pruritus
NCT01264224	PHASE1	COMPLETED	PAC-14028 in Healthy Male Volunteers
NCT02309008	PHASE1	COMPLETED	A Study to Assess the Safety, Tolerability and Pharmacokinetics of PAC-14028 Cream in Healthy Male Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

17 molecules share ≥1 primary target. Top 17 by shared-target count:

Molecule	Source	Status	Shared targets
CANNABIDIOL	ChEMBL	Phase 4 (approved)	TRPV1
CAPSAICIN	ChEMBL	Phase 4 (approved)	TRPV1
PROPOFOL	ChEMBL	Phase 4 (approved)	TRPV1
CANNABINOL	ChEMBL	Phase 3	TRPV1
FRAMYCETIN	ChEMBL	Phase 3	TRPV1
RESINIFERATOXIN	ChEMBL	Phase 3	TRPV1
ZUCAPSAICIN	ChEMBL	Phase 3	TRPV1
CANNABIDIVARIN	ChEMBL	Phase 2	TRPV1
CANNABIGEROL	ChEMBL	Phase 2	TRPV1
ILEPCIMIDE	ChEMBL	Phase 2	TRPV1
JTS-653	ChEMBL	Phase 2	TRPV1
MAVATREP	ChEMBL	Phase 2	TRPV1
NGD-8243	ChEMBL	Phase 2	TRPV1
OLVANIL	ChEMBL	Phase 2	TRPV1
PIPERINE	ChEMBL	Phase 2	TRPV1
SB-705498	ChEMBL	Phase 2	TRPV1
TETRAHYDROCANNABIVARIN	ChEMBL	Phase 2	TRPV1